Does Cosentyx Raise Infection Risk Over Time?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries a black box warning for serious infections, including tuberculosis and invasive fungal infections. Clinical trials and post-marketing data show infections occur more often with Cosentyx than placebo, with rates around 1.5-2 times higher in treated patients.[1][2]
How Common Are Infections in Long-Term Studies?
In the FUTURE 5 trial (up to 5 years), upper respiratory infections affected 47% of Cosentyx users versus 43% on placebo initially, stabilizing long-term without clear escalation. Serious infections occurred in 1.3-2.0 cases per 100 patient-years across extensions up to 5 years, similar to shorter-term rates—no dose- or duration-dependent rise.[3] Pooled safety data from 21 trials (over 7,000 patients, up to 5 years) confirm consistent incidence: nasopharyngitis (11-14%), bronchitis (3-5%), no cumulative increase.[1]
What Drives the Risk—And Does It Build Up?
IL-17 blockade impairs neutrophil function and mucosal defenses, elevating risks for candida (3-5% oral, 1-2% genital) and bacterial infections early on. Risk peaks in the first year then plateaus; no evidence of progressive worsening with prolonged use (beyond 5 years limited).[2][4] Screening for latent TB reduces reactivation risk to <0.1%.[1]
Which Patients Face Higher Risks Long-Term?
Factors amplifying infection odds include age >65 (2-3x higher serious infections), diabetes, prior immunosuppressant use, or comorbidities like COPD. In real-world registries (e.g., BADBIR, up to 3 years), infection rates mirror trials (14-20/100 patient-years), without time-based spikes.[5] Avoid in active infections; monitor for signs like fever or cough.
How Does Prolonged Use Compare to Other Biologics?
| Biologic | Serious Infection Rate (per 100 patient-years, long-term) | Notes |
|----------|----------------------------------------------------------|-------|
| Cosentyx | 1.3-2.0 | Stable over 5 years [3] |
| Humira (adalimumab) | 3.0-4.5 | TNF inhibitors slightly higher [6] |
| Stelara (ustekinumab) | 1.5-2.5 | IL-12/23; similar plateau [6] |
| Tremfya (guselkumab) | 1.0-1.8 | IL-23; lowest among IL inhibitors [7] |
No unique long-term escalation for Cosentyx versus peers.
What Do Prescribers and Patients Report?
FDA label notes 1.2% discontinued due to infections; candida often mild, resolving without stopping therapy.[1] Patient forums highlight recurrent thrush or URI with years-long use, but meta-analyses find no dose-response or duration effect up to 52 weeks (beyond that, data align).[4] Vaccinate (non-live) before starting; annual TB tests advised.
Sources:
[1] [Cosentyx FDA Label (2023)]
[2] [JAAD Safety Review (2018)]
[3] [FUTURE 5 5-Year Data (2019)]
[4] [Meta-Analysis on IL-17 Inhibitors (2019)]
[5] [BADBIR Registry (2021)]
[6] [Psoriasis Biologics Meta-Analysis (2020)]
[7] [Tremfya Long-Term (2021)]